Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 1: 197 - 204

DOI: https://doi.org/10.19852/j.cnki.jtcm.20231204.002

Original articles

Efficacy and safety of Chinese herbal medicine as adjunctive therapy in sepsis patients with bloodstream infection: a propensity-matched analysis

  • Xianshi ZHOU ,
  • Minlin ZHONG ,
  • Xiaotu XI ,
  • Jun LI ,
  • Guanghua TANG
Expand
  • 1 the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China; Emergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China; Guangdong Provincial Key Laboratory of Research on Emergency in TCM, Guangzhou 510120, China
    2 Emergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
    3 Emergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China; Guangdong Provincial Key Laboratory of Research on Emergency in TCM, Guangzhou 510120, China; Guangzhou Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Emerging Infectious Diseases, Guangzhou 510120, China
    4 Administration Department, the First Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China

Received date: 2022-11-11

  Accepted date: 2023-02-18

  Online published: 2023-12-04

Supported by

Clinical Research Program of Guangdong Provincial Hospital of Chinese Medicine: Exploring the Epidemiological Characteristics and Screening Key Prognostic Indicators of Sepsis Patients with Bloodstream Infection(2019KT1317);which is a sub-project of Guangdong Provincial Key Laboratory of Research on Emergency in TCM(2017B030314176)

Fold

Abstract

OBJECTIVE: To investigate the efficacy and safety of Chinese herbal medicine in treating sepsis patients with bloodstream infection.

METHODS: A 6-year retrospective study was carried out at a university hospital in China. Adult sepsis patients with bloodstream infection were included. The primary outcome was 28-day mortality after admission. Propensity score method was used to adjust for possible confounding. 28-day mortality was estimated by Kaplan-Meier analysis and compared using the log-rank test. Cox regression analysis was carried out to identify factors impacting in-hospital mortality outcomes.

RESULTS: Following the application of the propensity score method, a total of 176 patients were included. The all-cause 28-day mortality in the control group and Chinese herbal medicine group was 21.6% and 14.8%, respectively. Kaplan-Meier survival analysis showed that Chinese herbal medicine was associated with a lower hazard ratio (HR) in all-cause 28-day death compared with the control group [HR = 0.44, 95% CI(0.22, 0.90), P < 0.05]. The complications were similar between the two groups (P >0.05). Blood-activating and stasis-eliminating herb administration was associated with reduced in-hospital mortality among sepsis patients with bloodstream infection [HR = 0.54, 95% CI(0.34, 0.94), P < 0.05].

CONCLUSIONS: Chinese herbal medicine, especially the blood-activating and stasis-eliminating herb, might have certain efficacy and safety in treating sepsis patients with bloodstream infection. Clinicians should prescribe blood-activating and stasis-eliminating herb in treating these two coalescent critical diseases as long as no contraindications exist. However, further studies are needed to validate our results.

Key words： bacteremia; medicine, Chinese traditional; herbal medicine; sepsis; propensity-matched analysis

Cite this article

Xianshi ZHOU , Minlin ZHONG , Xiaotu XI , Jun LI , Guanghua TANG . Efficacy and safety of Chinese herbal medicine as adjunctive therapy in sepsis patients with bloodstream infection: a propensity-matched analysis[J]. Journal of Traditional Chinese Medicine, 2024 , 44(1) : 197 -204 . DOI: 10.19852/j.cnki.jtcm.20231204.002

References

1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-10.
2. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003; 29: 530-8.
3. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021; 47: 1181-247.
4. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016; 193: 259-72.
5. Biwersi C, Hepping N, Bode U, et al. Bloodstream infections in a German paediatric oncology unit: prolongation of inpatient treatment and additional costs. Int J Hyg Environ Health 2009; 212: 541-6.
6. Mehl A, ?svold BO, Lydersen S, et al. Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study. BMC Infect Dis 2017; 17: 205.
7. Ababneh MA, Rababa'h AM, Almomani BA, Ayoub AM, Al-Azzam SI. A ten-year surveillance of P aeruginosa bloodstream infections in a tertiary care hospital: trends and risk factors for mortality. Int J Clin Pract 2021; 75: e14409.
8. Amanati A, Sajedianfard S, Khajeh S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis 2021; 21: 636.
9. Laupland KB, Davies HD, Church DL, et al. Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study. Infection 2004; 32: 59-64.
10. Rodríguez-Ba?o J, de Cueto M, Retamar P, Gálvez-Acebal J. Current management of bloodstream infections. Expert Rev Anti Infect Ther 2010; 8: 815-29.
11. Liu QQ. Based on the four segments and treatment by syndrome differentiation to lower the mortality of sepsis. Chin J Integr Med 2009; 15: 16-8.
12. Lai F, Zhang Y, Xie DP, et al. A systematic review of Rhubarb (a Traditional Chinese Medicine) used for the treatment of experimental sepsis. Evid Based Complement Alternat Med 2015; 2015: 131283.
13. Wang Z, Chen W, Li Y, et al. Reduning injection and its effective constituent luteoloside protect against sepsis partly via inhibition of HMGB1/TLR4/NF-κB/MAPKs signaling pathways. J Ethnopharmacol 2021; 270: 113783.
14. Fan TT, Cheng BL, Fang XM, Chen YC, Su F. Application of Chinese medicine in the management of critical conditions: a review on sepsis. Am J Chin Med 2020; 48: 1315-30.
15. Zhao GZ, Chen RB, Li B, et al. Clinical practice guideline on Traditional Chinese Medicine therapy alone or combined with antibiotics for sepsis. Ann Transl Med 2019; 7: 122.
16. Vincent JL, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med 1996; 22: 707-10.
17. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 337-42.
18. Al Mohajer M, Darouiche RO. Sepsis syndrome, bloodstream infections, and device-related infections. Med Clin North Am 2012; 96: 1203-23.
19. Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol 2018; 14: 417-27.
20. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ 2016; 353: i1585.
21. Yin J, Yu Z, Hou C, Peng Y, Xiao J, Jiang J. Protective Effect of Zuojin Fang on lung injury induced by sepsis through downregulating the JAK1/STAT3 signaling pathway. Biomed Res Int 2021; 2021: 1419631.
22. Ma H, Kou J, Zhu D, Yan Y, Yu B. Liu-Shen-Wan, a Traditional Chinese Medicine, improves survival in sepsis induced by cecal ligation and puncture via reducing TNF-alpha levels, MDA content and enhancing macrophage phagocytosis. Int Immunopharmacol 2006; 6: 1355-62.
23. Liu J, Wang Z, Lin J, et al. Xuebijing injection in septic rats mitigates kidney injury, reduces cortical microcirculatory disorders, and suppresses activation of local inflammation. J Ethnopharmacol 2021; 276: 114199.
24. Gao M, Ou H, Jiang Y, et al. Tanshinone ⅡA attenuates sepsis-induced immunosuppression and improves survival rate in a mice peritonitis model. Biomed Pharmacother 2019; 112: 108609.
25. Xing X, Zhi Y, Lu J, et al. Traditional Chinese Medicine bundle therapy for septic acute gastrointestinal injury: a multicenter randomized controlled trial. Complement Ther Med 2019; 47: 102194.
26. Li C, Wang P, Zhang L, et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a Meta-analysis of randomized controlled trials. J Ethnopharmacol 2018; 224: 512-21.
27. Li MQ, Pan CG, Wang XM, et al. Effect of the Shenfu injection combined with early goal-directed therapy on organ functions and outcomes of septic shock patients. Cell Biochem Biophys 2015; 72: 807-12.
28. Liang X, Zhou M, Ge XY, et al. Efficacy of Traditional Chinese Medicine on sepsis: a systematic review and Meta-analysis. Int J Clin Exp Med 2015; 8: 20024-34.
29. Zhang Y, Du M, Chang Y, Chen LA, Zhang Q. Incidence, clinical characteristics, and outcomes of nosocomial enterococcus spp. bloodstream infections in a tertiary-care hospital in Beijing, China: a four-year retrospective study. Antimicrob Resist Infect Control 2017; 6: 73.
30. Raghunathan K, Shaw A, Nathanson B, et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med 2014; 42: 1585-91.
31. Iba T, Umemura Y, Wada H, Levy JH. Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment. Arch Med Res 2021; 52: 788-97.
32. Giustozzi M, Ehrlinder H, Bongiovanni D, et al. Coagulopathy and sepsis: pathophysiology, clinical manifestations and treatment. Blood Rev 2021; 50: 100864.
33. Tsao CM, Ho ST, Wu CC. Coagulation abnormalities in sepsis. Acta Anaesthesiol Taiwan 2015; 53: 16-22.
34. Ying J, Wu J, Zhang Y, et al. Ligustrazine suppresses renal NMDAR1 and caspase-3 expressions in a mouse model of sepsis-associated acute kidney injury. Mol Cell Biochem 2020; 464: 73-81.
35. Meng ZJ, Wang C, Meng LT, Bao BH, Wu JH, Hu YQ. Sodium tanshinone ⅡA sulfonate attenuates cardiac dysfunction and improves survival of rats with cecal ligation and puncture-induced sepsis. Chin J Nat Med 2018; 16: 846-55.
36. Zhu W, Lu Q, Wan L, Feng J, Chen HW. Sodium tanshinone Ⅱ A sulfonate ameliorates microcirculatory disturbance of small intestine by attenuating the production of reactie oxygen species in rats with sepsis. Chin J Integr Med 2016; 22: 745-51.
Options
Outlines

/

〈 〉